158 related articles for article (PubMed ID: 31715538)
21. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
22. Anti-PD-1 immunotherapy with adjuvant ablative fractional laser displays increased tumour clearance of squamous cell carcinoma, a murine study.
Christensen RL; Wiinberg M; Lerche CM; Demehri S; Olesen UH; Haedersdal M
Exp Dermatol; 2024 Feb; 33(2):e15013. PubMed ID: 38414090
[TBL] [Abstract][Full Text] [Related]
23. Update of cetuximab for non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
25. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
26. [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab].
Vanhakendover L; Lebas E; Libon F; Wauters O; Dezfoulian B; Marchal N; Rorive A; Piret P; Quatresooz P; Jacquemin D; Nikkels AF
Rev Med Liege; 2019 Jul; 74(7-8):436-440. PubMed ID: 31373461
[TBL] [Abstract][Full Text] [Related]
27. Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
Mangana J; Cheng PF; Kaufmann C; Amann VC; Frauchiger AL; Stögner V; Held U; von Moos R; Michielin O; Braun RP; Levesque MP; Goldinger SM; Dummer R
Melanoma Res; 2017 Aug; 27(4):358-368. PubMed ID: 28509765
[TBL] [Abstract][Full Text] [Related]
28. Evolving Role of Systemic Therapies in Non-melanoma Skin Cancer.
Conforti C; Corneli P; Harwood C; Zalaudek I
Clin Oncol (R Coll Radiol); 2019 Nov; 31(11):759-768. PubMed ID: 31522944
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral T; Meraz-Torres F; Garbe C
Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma.
Patel R; Chang ALS
Am J Clin Dermatol; 2019 Aug; 20(4):477-482. PubMed ID: 30737731
[TBL] [Abstract][Full Text] [Related]
31. Skin cancer precursor immunotherapy for squamous cell carcinoma prevention.
Rosenberg AR; Tabacchi M; Ngo KH; Wallendorf M; Rosman IS; Cornelius LA; Demehri S
JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30895944
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents.
Cavalieri S; Perrone F; Milione M; Bianco A; Alfieri S; Locati LD; Bergamini C; Resteghini C; Galbiati D; Platini F; Licitra L; Bossi P
Oncology; 2019; 97(2):112-118. PubMed ID: 31112973
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
35. Patterns of immunotherapy use and management of toxicities in regional and tertiary settings.
Hamilton B; Xu K; Honeyball F; Balakrishnar B; Zielinski R
Intern Med J; 2019 Aug; 49(8):1010-1015. PubMed ID: 30693623
[TBL] [Abstract][Full Text] [Related]
36. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?
Ribero S; Stucci LS; Daniels GA; Borradori L
Curr Opin Oncol; 2017 Mar; 29(2):129-135. PubMed ID: 28151757
[TBL] [Abstract][Full Text] [Related]
37. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.
Anforth R; Menzies A; Byth K; Carlos G; Chou S; Sharma R; Scolyer RA; Kefford R; Long GV; Fernandez-Peñas P
J Am Acad Dermatol; 2015 May; 72(5):809-15.e1. PubMed ID: 25748298
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor inhibition by anti-CD147 therapy in cutaneous squamous cell carcinoma.
Frederick JW; Sweeny L; Hartman Y; Zhou T; Rosenthal EL
Head Neck; 2016 Feb; 38(2):247-52. PubMed ID: 25270595
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations.
Martinez JC; Otley CC; Okuno SH; Foote RL; Kasperbauer JL
Dermatol Surg; 2004 Apr; 30(4 Pt 2):679-86. PubMed ID: 15061855
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]